Investment analysts at Leerink Swann lifted their price objective on shares of Cubist Pharmaceuticals (NASDAQ:CBST) from $76.00 to $80.00 in a note issued to investors on Tuesday, AnalystRatings.NET reports. Leerink Swann’s price target would indicate a potential upside of 13.06% from the company’s current price.
Cubist Pharmaceuticals (NASDAQ:CBST) traded down 2.61% on Tuesday, hitting $68.91. 389,155 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 1-year low of $38.53 and a 1-year high of $68.00. The stock’s 50-day moving average is $63.74 and its 200-day moving average is $58.83. The company has a market cap of $5.103 billion and a price-to-earnings ratio of 183.79. Cubist Pharmaceuticals also was the recipient of some unusual options trading activity on Monday. Stock traders purchased 22,840 put options on the company. This represents an increase of 942% compared to the typical daily volume of 2,192 put options.
Cubist Pharmaceuticals (NASDAQ:CBST) last posted its quarterly earnings results on Thursday, October 17th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.07. The company had revenue of $266.00 million for the quarter, compared to the consensus estimate of $267.96 million. During the same quarter in the prior year, the company posted $0.55 earnings per share. The company’s quarterly revenue was up 11.7% on a year-over-year basis. Analysts expect that Cubist Pharmaceuticals will post $-0.11 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group raised their price target on shares of Cubist Pharmaceuticals from $76.00 to $82.00 in a research note to investors on Tuesday. Separately, analysts at Morgan Stanley initiated coverage on shares of Cubist Pharmaceuticals in a research note to investors on Wednesday, November 13th. They set an “overweight” rating and a $85.00 price target on the stock. Finally, analysts at Thomson Reuters/Verus downgraded shares of Cubist Pharmaceuticals from a “hold” rating to a “sell” rating in a research note to investors on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $66.71.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.